Strata Critical Medical (SRTA) Capital Expenditures (2021 - 2026)

Strata Critical Medical (SRTA) has 6 years of Capital Expenditures data on file, last reported at $5.2 million in Q1 2026.

• Quarterly Capital Expenditures rose 1427.73% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 132.72% YoY) and the FY2025 annual result came in at $128000.0, down 65.87% from the prior year.
• Capital Expenditures improved to $5.2 million in Q1 2026 per SRTA's latest filing, from -$7.6 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $7.6 million in Q3 2024 and bottomed at -$25.9 million in Q4 2024.
• The 5-year median for Capital Expenditures is $816000.0 (2024), against an average of -$641307.7.
• The widest annual swing landed in 2024, when Capital Expenditures tumbled 1142.73%; it then jumped 1427.73% in 2026.
• Tracing SRTA's Capital Expenditures over 5 years: stood at $626000.0 in 2022, then slumped by 433.07% to -$2.1 million in 2023, then plunged by 1142.73% to -$25.9 million in 2024, then jumped by 70.6% to -$7.6 million in 2025, then soared by 167.97% to $5.2 million in 2026.
• Per Business Quant, the three latest SRTA Capital Expenditures figures stand at $5.2 million (Q1 2026), -$7.6 million (Q4 2025), and $2.8 million (Q3 2025).

Peer Comparison